Michael H. Davidson to Pyridines
This is a "connection" page, showing publications Michael H. Davidson has written about Pyridines.
Connection Strength
0.492
-
Controversy surrounding the safety of cerivastatin. Expert Opin Drug Saf. 2002 Sep; 1(3):207-12.
Score: 0.187
-
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol. 2013 Mar-Apr; 7(2):102-8.
Score: 0.093
-
Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009 Jan; 11(1):67-70.
Score: 0.073
-
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf. 2004 Nov; 3(6):547-57.
Score: 0.054
-
Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. Am J Cardiol. 2001 Sep 15; 88(6):635-9.
Score: 0.044
-
Statin trials in progress: unanswered questions. Curr Atheroscler Rep. 2001 Jan; 3(1):9-13.
Score: 0.042